BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saibeni S, Bollani S, Losco A, Michielan A, Sostegni R, Devani M, Lupinacci G, Pirola L, Cucino C, Meucci G. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012;44:123-127. [PMID: 22051323 DOI: 10.1016/j.dld.2011.09.015] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
2 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rouiller-Braunschweig C, Fournier N, Pittet V, Dudler J, Michetti P. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients. Digestion 2017;96:220-7. [PMID: 29065423 DOI: 10.1159/000482007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Janíková-bandžuchová L, Šelešovská R. Determination of Methotrexate at a Silver Solid Amalgam Electrode by Differential Pulse Voltammetry. Analytical Letters 2015;49:122-34. [DOI: 10.1080/00032719.2014.996812] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
5 Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:224-33. [PMID: 26457382 DOI: 10.1097/MIB.0000000000000589] [Cited by in Crossref: 61] [Cited by in F6Publishing: 18] [Article Influence: 10.2] [Reference Citation Analysis]
6 Quezada SM, Mclean LP, Cross RK. Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology 2018;12:1183-91. [DOI: 10.1080/17474124.2018.1545574] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
7 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
8 Miele E, Shamir R, Aloi M, Assa A, Braegger C, Bronsky J, de Ridder L, Escher JC, Hojsak I, Kolaček S, Koletzko S, Levine A, Lionetti P, Martinelli M, Ruemmele F, Russell RK, Boneh RS, van Limbergen J, Veereman G, Staiano A. Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology & Nutrition 2018;66:687-708. [DOI: 10.1097/mpg.0000000000001896] [Cited by in Crossref: 59] [Cited by in F6Publishing: 23] [Article Influence: 14.8] [Reference Citation Analysis]
9 Mollaei M, Ghoreishi SM, Khoobi A. Nano-molar level detection of calcium folinate and methotrexate using a cationic surfactant and multivariate optimization: A simple tool for simultaneous and sensitive analysis. Measurement 2020;152:107362. [DOI: 10.1016/j.measurement.2019.107362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gabbani T, Deiana S, Lunardi S, Manetti N, Annese V. Safety profile of methotrexate in inflammatory bowel disease. Expert Opinion on Drug Safety 2016;15:1427-37. [DOI: 10.1080/14740338.2016.1218468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
11 Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. Eur J Gastroenterol Hepatol 2018;30:612-20. [PMID: 29384798 DOI: 10.1097/MEG.0000000000001078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lee LYW, Gardezi AS, Santharam V, Boyd J, Lanzon-Miller S. Effect of azathioprine intolerance on outcomes of inflammatory bowel disease: a cross-sectional study. Frontline Gastroenterol 2014;5:40-3. [PMID: 28839749 DOI: 10.1136/flgastro-2013-100348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017;37:475-89. [PMID: 27712010 DOI: 10.1111/liv.13265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
14 Vaccaro JA, Naser SA. The Role of Methyl Donors of the Methionine Cycle in Gastrointestinal Infection and Inflammation. Healthcare 2022;10:61. [DOI: 10.3390/healthcare10010061] [Reference Citation Analysis]
15 Nejati S, Wang J, Heredia-Rivera U, Sedaghat S, Woodhouse I, Johnson JS, Verma M, Rahimi R. Small intestinal sampling capsule for inflammatory bowel disease type detection and management. Lab Chip 2021;22:57-70. [PMID: 34826326 DOI: 10.1039/d1lc00451d] [Reference Citation Analysis]
16 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Grosen A, Kelsen J, Hvas CL, Bellaguarda E, Hanauer SB. The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure. Inflamm Bowel Dis 2017;23:561-9. [PMID: 28267049 DOI: 10.1097/MIB.0000000000001064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
18 Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. World J Gastroenterol 2013; 19(42): 7327-7340 [PMID: 24259964 DOI: 10.3748/wjg.v19.i42.7327] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 54] [Article Influence: 7.0] [Reference Citation Analysis]
19 LeBlanc JF, Wiseman D, Lakatos PL, Bessissow T. Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. World J Gastroenterol 2019; 25(30): 4158-4171 [PMID: 31435170 DOI: 10.3748/wjg.v25.i30.4158] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021; 13(11): 1534-1551 [PMID: 34904028 DOI: 10.4254/wjh.v13.i11.1534] [Reference Citation Analysis]
21 de Bruyn M, Vandooren J, Ugarte-berzal E, Arijs I, Vermeire S, Opdenakker G. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Critical Reviews in Biochemistry and Molecular Biology 2016;51:295-358. [DOI: 10.1080/10409238.2016.1199535] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
22 Guslandi M. Methotrexate for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2013;11:1039. [DOI: 10.1016/j.cgh.2013.02.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Kolli VK, Natarajan K, Isaac B, Selvakumar D, Abraham P. Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis. Hum Exp Toxicol 2014;33:1051-65. [PMID: 24347301 DOI: 10.1177/0960327113515503] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
24 Šelešovská R, Janíková-bandžuchová L, Chýlková J. Sensitive Voltammetric Sensor Based on Boron-Doped Diamond Electrode for Determination of the Chemotherapeutic Drug Methotrexate in Pharmaceutical and Biological Samples. Electroanalysis 2015;27:42-51. [DOI: 10.1002/elan.201400326] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
25 Calafat M, Mañosa M, Cañete F, Domènech E. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs Aging 2021;38:193-203. [PMID: 33438138 DOI: 10.1007/s40266-020-00832-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Herfarth HH, Long MD, Isaacs KL. Methotrexate: underused and ignored? Dig Dis 2012;30 Suppl 3:112-8. [PMID: 23295701 DOI: 10.1159/000342735] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
27 Gomollón F, Rubio S, Charro M, García-López S, Muñoz F, Gisbert JP, Domènech E; En Representación de GETECCU. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. Gastroenterol Hepatol 2015;38:24-30. [PMID: 25454602 DOI: 10.1016/j.gastrohep.2014.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
28 González-lama Y, Taxonera C, López-sanromán A, Pérez-calle JL, Bermejo F, Pajares R, Mcnicholl AG, Opio V, Mendoza JL, López P, Algaba A, Estelles J, Barbero A, Mendoza J, Maté J, Gisbert JP. Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. European Journal of Gastroenterology & Hepatology 2012;24:1086-91. [DOI: 10.1097/meg.0b013e3283556db5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
29 Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. Eur J Pharm Biopharm 2021;167:89-103. [PMID: 34329709 DOI: 10.1016/j.ejpb.2021.07.014] [Reference Citation Analysis]
30 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
31 Cesarini M, Festa S, Papi C. Methotrexate in Crohn’s disease: a new face for an old drug? Expert Review of Gastroenterology & Hepatology 2016;10:1135-44. [DOI: 10.1080/17474124.2016.1185363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Kolli VK, Kanakasabapathy I, Faith M, Ramamoorthy H, Isaac B, Natarajan K, Abraham P. A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation. Cancer Chemother Pharmacol 2013;71:1209-18. [PMID: 23420439 DOI: 10.1007/s00280-013-2115-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
33 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 76] [Article Influence: 13.0] [Reference Citation Analysis]
34 Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;CD006618. [PMID: 25162749 DOI: 10.1002/14651858.cd006618.pub3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
35 Khan N, Abbas AM, Moehlen M, Balart L. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System. Inflamm Bowel Dis. 2013;19:1379-1383. [PMID: 23542534 DOI: 10.1097/mib.0b013e31828133e8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
36 Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [DOI: 10.4254/wjh.v14.i2.319] [Reference Citation Analysis]
37 Kim D, Taleban S. A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population. Drugs Aging 2019;36:607-24. [PMID: 31055789 DOI: 10.1007/s40266-019-00672-x] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
39 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
40 Cassinotti A, Batticciotto A, Parravicini M, Lombardo M, Radice P, Cortelezzi CC, Segato S, Zanzi F, Cappelli A, Segato S. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol 2022;15:17562848221085889. [PMID: 35340755 DOI: 10.1177/17562848221085889] [Reference Citation Analysis]
41 Natarajan K, Abraham P, Kota R, Selvakumar D. Aminoguanidine pretreatment prevents methotrexate-induced small intestinal injury in the rat by attenuating nitrosative stress and restoring the activities of vital mitochondrial enzymes. Journal of Basic and Clinical Physiology and Pharmacology 2017;28. [DOI: 10.1515/jbcpp-2016-0099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]